Propranolol stereoisomer plasma concentrations and portal haemodynamic response in patients with liver cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 11, 1999, Pages 1451-1458

  Schepke, M ^a   Raab, P ^a   Hoppe, A ^a   Brensing, K A ^a   Paar, D ^a   Potyka, U ^a   Sauerbruch, T ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROPRANOLOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILIARY CIRRHOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HEART RATE; HEMODYNAMICS; HUMAN; MALE; MEAN ARTERIAL PRESSURE; ORAL DRUG ADMINISTRATION; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RACEMIC MIXTURE; STEREOCHEMISTRY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PORTAL; LIVER CIRCULATION; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROPRANOLOL; STEREOISOMERISM;

EID: 0032702540     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00622.x     Document Type: Article

References (30)

1. 1 D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332-54.
2. 2 Poynard T, Cales P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med 1991; 324: 1532-8.
3. 3 Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. N Engl J Med 1981; 305: 1371-4.
4. 4 Lebrec D, Hillon P, Munoz C, Goldfarb G, Nouel O, Benhamou JP. The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology 1982; 2: 523-7.
5. 5 Hillon P, Lebrec D, Munoz C, Jungers M, Goldfarb G, Benhamou JP. Comparison of the effects of a cardioselective and nonselective beta-blocker on portal hypertension in patients with cirrhosis. Hepatology 1982; 2: 528-31.
6. 6 Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized clinical trial of propranolol versus placebo in the prevention of first variceal hemorrhage. Gastroenterology 1990; 99: 1401-7.
7. 7 Feu F, Garcia-Pagan JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346: 1056-9.
8. 8 Villanueva C, Balanzo J, Novella MT, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334: 1624-9.
9. 9 Bosch J, Mastai R, Kravetz D, et al. Effects of propranolol on azygos blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984; 4: 1200-5.
10. 10 Garcia-Tsao G, Grace ND, Groszmann RJ, et al. Short-term effects of propranolol on portal venous pressure. Hepatology 1986; 6: 101-6.
11. 11 Vorobioff J, Picabea E, Villavicencio R, et al. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 1987; 7: 648-53.
12. 12 Albillos A, Perez-Paramo M, Cacho G, et al. Accuracy of portal and forearm blood flow measurements in the assessment of the portal pressure response to propranolol. J Hepatol 1997; 27: 496-504.
13. 13 Mills PR, Rae AP, Farah DA, Russell RI, Lorimer AR, Carter DC. Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension. Gut 1984; 25: 73-8.
14. 14 Arthur MJP, Tanner AR, Patel C, Wright R, Renwick AG, George CF. Pharmacology of propranolol in patients with cirrhosis and portal hypertension. Gut 1989; 26: 14-19.
15. 15 Stark G, Stark U, Hönigl K, et al. The effects of the propranolol enantiomers on the intracardiac electrophysiological activities of Langendorff-perfused hearts. Basic Res Cardiol; 84: 461-8.
16. 16 Stoschitzky K, Lindner W, Rath M, et al. Stereoselective hemodynamic effects of (R)- and (S)-propranolol in man. Naunyn-Schmiedeberg's Arch Pharmacol 1989; 339: 474-8.
17. 17 Stoschitzky K, Lindner W, Egginger G, et al. Racemic (R.S)-propranolol versus half-dosed optically pure (S)-propranolol in humans at steady state: hemodynamic effects, plasma concentrations and influence on thyroid hormone levels. Clin Pharmacol Ther 1992; 51: 445-53.
18. 18 Walle T, Webb JG, Ragwell E, Walle U, Daniell HB, Gaffney TE. Stereoselective delivery and actions of beta receptor antagonists. Biochem Pharmacol 1988; 37: 115-24.
19. 19 Neugebauer G, Gabor M, Reiff K. Disposition of carvedilol enantiomers in patients with liver cirrhosis: Evidence for disappearance of first-pass extraction. J Cardiovasc Pharmacol 1992; 19(Suppl. 1): S142-6.
20. 20 Stahl E, Baumgartner U, Henke U, Schölmerich J, Mutschler E, Spahn-Langguth H. Rats with portacaval shunt as a potential experimental model for liver cirrhosis: application to carvedilol stereopharmacokinetics. Chirality 1993; 5: 1-7.
21. 21 Branch RA, James J, Read AE. A study of factors influencing drug disposition in chronic liver disease using the model drug (+)-propranolol. Br J Clin Pharmacol 1976; 3: 243-9.
22. 22 Pessayre D, Lebrec D, Descatoire V, Peignoux M, Benhamou JP. Mechanism for reduced drug clearance in patients with cirrhosis. Gastroenterology 1978; 74: 566-71.
23. 23 Spahn-Langguth H, Podkowik B, Stahl E, Martin E, Mutschler E. Improved enantiospecific RP-HPLC assays for Propranolol in plasma and urine with Pronethalol as internal standard. J Anal Toxicol 1991; 15: 327-31.
24. 24 Lebrer C, Nouel O, Corbic M, Benhamou JP. Propranolol - a medical treatment for portal hypertension? Lancet 1980; 2: 180-2.
25. 25 Shand DG, Ragno RE. The disposition of Propranolol I. Elimination during oral absorption in man. Pharmacology 1972; 7: 159-68.
26. 26 Bercoff E, Bataille C, Pariente AE, Valla D, Delhotal B, Lebrec D. Assessment of β-adrenergic blockade with propranolol in patients with cirrhosis. Hepatology 1984; 4: 451-3.
27. 27 Jiron M, Delhotal B, Lebrec D. Relationship between dose, blood level and haemodynamic response in patients with cirrhosis receiving propranolol. Eur J Clin Pharmacol 1985; 28: 353-5.
28. 48 Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transsection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
29. 29 Piquette-Miller M, Foster RT, Kappagoda CT, Jamali F. Effect of aging on the pharmacokinetics of Acebutolol enantiomers. J Clin Pharmacol 1992; 32: 148-56.
30. 30 Poynard T, Lebrec D, Hillon P, et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a prospective study of factors associated with rebleeding. Hepatology 1987; 7: 447-51.